Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phelan-McDermid Syndrome Clear all

Conditions: Fragile X Syndrome, Angelman Syndrome, Prader-Willi Syndrome, Dup15Q Syndrome, Duchenne Muscular Dystrophy, Phelan-McDermid Syndrome, Rett Syndrome, Smith Magenis Syndrome, Williams Syndrome, Turner Syndrome, Klinefelter Syndrome, Chromosome 22q11.2 Deletion Syndrome, Tuberous Sclerosis, Down Syndrome
Interventions: Parent-Infant Inter(X)action Intervention (PIXI); Behavioral
Lead sponsor: RTI International; Other
Eligibility: Up to 99 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Phelan-McDermid Syndrome, Autism Spectrum Disorder, Intellectual Disability
Interventions: No Intervention; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 22 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Stanford, California • Chicago, Illinois • Bethesda, Maryland + 3 more

Conditions: Microdeletion Syndromes, Trisomy 21, Trisomy 18, Trisomy 13, Sex Chromosome Abnormalities
Interventions: Not listed
Lead sponsor: Natera, Inc.; Industry
Eligibility: Not listed
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: San Carlos, California • Philadelphia, Pennsylvania

Conditions: Phelan-McDermid Syndrome
Interventions: Not listed
Lead sponsor: University of Arkansas; Other
Eligibility: 1 Year to 21 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Phelan-McDermid Syndrome
Interventions: NNZ-2591; Drug
Lead sponsor: Neuren Pharmaceuticals Limited; Industry
Eligibility: 3 Years to 12 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • Houston, Texas

Conditions: Phelan-McDermid Syndrome
Interventions: NNZ-2591, Placebo; Drug
Lead sponsor: Neuren Pharmaceuticals Limited; Industry
Eligibility: 3 Years to 12 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 17
States / cities: Birmingham, Alabama • Glendale, California • Palo Alto, California + 14 more

Conditions: Phelan-McDermid Syndrome, Autism Spectrum Disorder, Intellectual Disability
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Months and older
Enrollment: 207 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2026
U.S. locations: 5
States / cities: Stanford, California • Chicago, Illinois • Bethesda, Maryland + 2 more

Conditions: Phelan-McDermid Syndrome, Epilepsy
Interventions: AMO-01; Drug
Lead sponsor: Alexander Kolevzon; Other
Eligibility: 12 Years to 45 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Phelan McDermid Syndrome
Interventions: Recombinant human Growth hormone; Drug
Lead sponsor: Swathi Sethuram; Other
Eligibility: 2 Years to 12 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Telomeric 22Q13 Monosomy Syndrome, Tuberous Sclerosis, Hamartoma Syndrome, Multiple, Fragile X Syndrome, Angelman Syndrome, Rett Syndrome, Chromosome 15Q, Partial Deletion, Creatine Deficiency, X-linked
Interventions: Functional Behavioral Training (FBT), Positive Parenting Strategies-Treatment as Usual; Behavioral · Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 2 Years to 12 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Phelan-McDermid Syndrome, Autism Spectrum Disorder (ASD)
Interventions: Growth Hormone, Saline; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 2 Years to 12 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: SHANK3 Haploinsufficiency, Phelan-McDermid Syndrome
Interventions: JAG201; Genetic
Lead sponsor: Jaguar Gene Therapy, LLC; Industry
Eligibility: 2 Years to 9 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 3
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York

Conditions: 22q13 Deletion Syndrome, Phelan-McDermid Syndrome
Interventions: Insulin-Like Growth Factor-1 (IGF-1), Normal saline; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 5 Years to 12 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Phelan-McDermid Syndrome
Interventions: NNZ-2591; Drug
Lead sponsor: Neuren Pharmaceuticals Limited; Industry
Eligibility: 3 Years to 12 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • Glendale, California • San Diego, California + 9 more

Conditions: Phelan-McDermid Syndrome
Interventions: Oxytocin, Saline; Drug
Lead sponsor: Alexander Kolevzon; Other
Eligibility: 5 Years to 17 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Parent and Infant Inter(X)Action Intervention (PIXI)

Mapping the Phenotype in Adults With Phelan-McDermid Syndrome

Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA

Mitochondrial Dysfunction in Phelan-McDermid Syndrome

An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)

A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome

AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy

Growth Hormone Treatment in Children With Phelan McDermid Syndrome

Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)

A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism

JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency

Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)

An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome